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Abstract
Background: Early diagnosis of dengue infection is important for decision-making and timely implementation of
therapeutic measures. Although rapid NS1 assays have been used for dengue diagnosis since 2008, their
performance in DENV-4 cases has not yet been fully assessed.
Methods: We evaluated the accuracy of NS1 Bioeasy™ immunochromatographic strip test and of three clinical
criteria for dengue diagnosis. Patients presenting at an emergency care center within 72 h of an acute febrile illness
during the 2013 DENV-4 epidemic in Rio de Janeiro were consecutively enrolled for clinical and laboratory
evaluation. We classified patients as suspected dengue or not according to three clinical criteria: WHO 2009, WHO
1997, and INI-FIOCRUZ. Dengue diagnosis was defined by RNA detection using RT-PCR and the negative cases were
negative for all dengue serotypes and also Platelia™ NS1 ELISA. We obtained accuracy indices for NS1 Bioeasy™
alone and in combination with the clinical criteria.
Results: RT-PCR for DENV-4 was positive in 148 out of 325 patients. Positive likelihood ratio, sensitivity, and
specificity of NS1 Bioeasy™ with WHO 2009, WHO 1997, and INI-FIOCRUZ criteria were 22.6 (95 % CI 7.2–70.6),
40.6 % (95 % CI 32.3–49.3), and 98.2 % (95 % CI 94.9–99.6); 18.3 (95 % CI 6.8–49.2), 44.2 (95 % CI 35.8–52.9), 97.6
(95 % CI 94.0–99.3); 26.2 (95 % CI 6.5–106.5), 29.7 (95 % CI 22.4–37.8), 98.9 (95 % CI 96.0–99.9), respectively. WHO
1997 clinical criteria presented high sensitivity to rule out disease, but extremely low specificity. INI-FIOCRUZ had
moderate sensitivity and specificity, and could target a group to a more specific test.
Conclusions: Although the large rates of false negative results using NS1 Bioeasy™ rapid test advise against its use
for triaging (rule out) purposes in DENV-4 epidemics, it could be used as a confirmatory tool in a bedside algorithm.
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Background
Dengue is an acute viral febrile disease mainly transmitted
by the Aedes aegypti mosquito. Dengue virus has four se-
rotypes (DENV 1-4) defined by phylogenetic and antigenic
characteristics. The immunity resulting from infection is
serotype-specific and does not protect the individual
against other serotypes [1].
A recent study estimated that about 390 million cases of
dengue occurred in 2010, which is more than three times
the World Health Organization (WHO) estimates for that
same period [2]. However, only 96 million were symptom-
atic. Brazil has the highest dengue reporting rates world-
wide and between 2000 and 2007, over three million cases
were reported in the country, corresponding to approxi-
mately 60 % of cases in the Americas [3].
In Brazil, dengue outbreaks have occurred yearly since
1986 and during epidemic seasons the entire health care
system is overwhelmed by a three to four-fold increase in
patient visits. In the state of Rio de Janeiro, epidemics
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occurred in 1986 [4], 1990 [5], 2000 [6], and 2008 [7] by
DENV-1, DENV-2, DENV-3, and by the reemergence of
DENV-2, respectively, usually followed by dissemination
to other regions of the country. DENV-4 was first identi-
fied in this Brazilian state in 2011 [8] and accounted for
218,000 reported cases in the 2013 epidemic.
Early diagnosis is critical because some patients may
progress from a mild to a severe disease in a short period
of time [9, 10]. Repeated monitoring of platelet count and
hematocrit is recommended, as an abrupt decrease in
platelet count is a warning sign and a significant
hematocrit increase is an indirect sign of plasma leakage
[7]. In 1997, WHO proposed as a dengue clinical case a
patient that presented with fever and two or more of the
following: headache, retro-orbital pain, myalgia, arthralgia,
rash, hemorrhagic manifestations, and leukopenia [11].
However, due to the low specificity (36 %) of these criteria
[12], a new set was proposed in 2009 that grouped myalgia
and arthralgia in body aches, included nausea and vomit-
ing, and added some warning signs and symptoms [1].
The 80 % sensitivity and 57 % specificity of the newly
proposed WHO criteria [12], supports the importance of
laboratory confirmation.
A previous study carried out at the Evandro Chagas
National Institute of Infectious Diseases, Oswaldo Cruz
Foundation (INI-FIOCRUZ) in Rio de Janeiro analyzed
clinical and hematological data in ambulatory febrile pa-
tients and derived another diagnostic set of clinical criteria
for dengue diagnosis [13]. In this study population the
prediction rule, based on the presence of conjunctival
hyperemia and leukocyte count, shown 81 % sensitivity
and 71 % specificity [13].
Dengue laboratory diagnosis can be performed directly,
by identifying the virus or its components, or indirectly,
through serological tests detecting antibodies produced
against the virus. The sensitivity of each method relies on
disease duration at the moment of the clinical specimen
collection [14]. The indirect methods are the more com-
monly used but have limited usefulness in the acute den-
gue diagnosis. IgM peaks occur around the third to fourth
day of disease onset, and therefore a second clinical speci-
men collection is needed around day 14 to confirm the
IgM rise and conclusively diagnose the disease [15].
However, in scenarios where the prevalence of second-
ary dengue is high, such as in Rio de Janeiro State, the
duration and magnitude of the IgM response is reduced
possibly impairing the accuracy of this serologic param-
eter [16]. Furthermore, pairing IgM are usually not
point-of-care techniques, limiting their usefulness in
epidemic scenarios.
During the febrile phase, detection of viral RNA or non-
structural protein-1 (NS1) are the main methods for the
disease diagnosis. However, detection of viral RNA by re-
verse transcriptase-polymerase chain reaction (RT-PCR) is
relatively complex and expensive, and is therefore not
feasible in a number of health care settings, particularly in
epidemic situations. For this reason, the identification of
NS1 has been suggested as an alternative because it is
present in the virus membrane, is highly stable and is
secreted in the human serum during the early phase of
dengue infection [15]. The sensitivity of the NS1 ELISA is
reported to be greater than 90 % in primary infections and
varies from 60 to 80 % in secondary infections [17, 18].
The rapid detection of dengue NS1 by immunochro-
matographic methods represents a potential break-
through for laboratory case confirmation at early stages
of disease in settings with limited infrastructure because
they require minimal laboratory expertise and provide
results within 15 to 30 min of specimen reception [4, 15,
19]. This laboratory technique, first described in 2000
and widely used since 2008, has now been tested in all
dengue scenarios, especially in DENV-1 and DENV-3
scenarios [12, 15]. However, DENV-4 samples are still
underrepresented [15, 18, 20, 21].
Ferraz, et al. [22], when evaluating mainly Brazilian
DENV-1 samples by three different immunochromato-
graphic assays, identified the NS1 Bioeasy™ as the one
with higher sensitivity (63 %) despite the high specificity
presented by all three (100 %). Another Brazilian study
evaluating accuracy parameters of 4 immunochromato-
graphic tests in a panel of acute DENV-1 to DENV-3
concluded that NS1 Bioeasy™ presented an overall 68 %
specificity and a 90 % sensitivity which could reach 95 %
in a DENV-1 setting [23].
A simple and accurate test to diagnose acute dengue
cases in outpatient healthcare settings is still required.
Considering this issue, we evaluated the diagnostic ac-
curacy of three clinical dengue diagnostic criteria (WHO
1997, WHO 2009, INI-FIOCRUZ) and NS1 Bioeasy™
immunochromatographic test in an urgent care center




This prospective cross-sectional diagnostic accuracy study
is reported according to the Standards for Reporting of
Diagnostic Accuracy Study (STARD) Guideline [24] and
was approved by the Research Ethics Committee of the
Evandro Chagas National Institute of Infectious Diseases-
FIOCRUZ, CAAE 0066.0.009.000-11, on March 23, 2012.
Enrollment, data, and specimen collection
We conducted the study in the city of Rio de Janeiro, Rio
de Janeiro, Brazil, from March to April 2013, during an
ongoing dengue epidemic. Adult patients (age >18 years)
attending a public urgent care center (Unidade de Pronto
Atendimento-UPA 24H) within 72 h of onset of an acute
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febrile illness without an evident focus of infection were
eligible for the study.
A trained nurse obtained informed consent and pro-
spectively enrolled the patients during business hours 5
days a week. An infectious disease physician collected data
on demographic characteristics, symptoms and physical
signs using a summarized version of a previously pub-
lished and tested semi-structured questionnaire [25]. The
tourniquet test was not performed and only spontaneous
hemorrhagic manifestations were recorded.
We evaluated all patients according to WHO 1997,
WHO 2009, and INI-FIOCRUZ clinical criteria defined
elsewhere [1, 11, 13, 26].
Blood samples were collected for complete blood count
and specific dengue tests including NS1 Bioeasy™, RT-
PCR, Panbio® dengue IgM capture ELISA and dengue IgG
ELISA, and Platelia™ Dengue NS1 Ag-ELISA. Acute
dengue-4 cases were confirmed by RT-PCR. Serum
samples were sent to the Flavivirus Laboratory, a regional
reference laboratory for dengue and yellow fever at the
Oswaldo Cruz Foundation (FIOCRUZ) where they were




All febrile cases were tested by the NS1 Bioeasy™ immu-
nochromatographic strip test (Bioeasy™, Standard Diag-
nostics INC, Korea). This rapid test was chosen because it
has already been used in the state of Rio de Janeiro and in
other Brazilian states during dengue outbreaks. However,
its performance had not been previously assessed. Accord-
ing to the manufacturer’s instruction, the test can be
stored at room temperature and can adequately detect the
NS1 within 15 min using three drops of whole blood,
plasma or serum.
In the immunochromatographic strip test, the NS1
antigen present in the sample will complex with the gold
colloidal particles coated with anti-NS1 antibodies. After
migration, the complexes will be captured by anti-NS1
antibodies at the test line where a line will appear. The
presence of two lines in the cassette’s window means a
positive result, whereas the absence of the second line
means a negative result with an adequate control line,
which ensures the test is working properly.
Clinical criteria
Patients were classified as suspected dengue cases accord-
ing to three sets of clinical criteria described as follows:
WHO 1997: fever with two or more of the following:
headache, retro-orbital pain, myalgia, arthralgia, rash,
hemorrhagic manifestations, and leukopenia [11]; WHO
2009: fever with two or more of the following: nausea/
vomiting, rash, pain, leukopenia, and any of the following
warning signs: abdominal pain, persistent vomiting, edema,
mucosal bleeding, lethargy, hepatomegaly or hemoconcen-
tration associated with a sudden drop in platelet count [1];
and INI-FIOCRUZ: presence of conjunctival redness with
leukocytes less than 7500/mm3 or less than 3760 leuko-
cytes/mm3 independently of other signs or symptoms [13].
Hemoconcentration in a single sample was defined by
a hematocrit >53 % in males or 48 % in females [27].




In order to identify dengue viral RNA and specifically den-
gue 4 serotype, we performed RT-PCR according to the
protocol described by Lanciotti et al. [28]. This highly spe-
cific protocol suggested by WHO [1] was considered the
“gold standard” method for dengue-4 case confirmation in
this study. Briefly, consensus primers (D1-5′-TCAA
TATGCTGAAACGCGGAGAAACCG-3′) and D2 (5′-
TTGCACCAACAGTCAATGTCTTCAGGTTC-3′) were
annealed to any of the four dengue serotypes to amplify a
511-bp product in a reverse transcriptase-polymerase re-
action. After a second round of amplification (nested
PCR) with type-specific primers (TS1 [5′- CGTCTCAGT
GATCCGGGGG- 3′], TS2 [5′-CGCCACAAGGGCCAT
GAACAG-3′], TS3 [5′-TAACATCATCATGAGACAGA
GC-3′] and TS4 [5′-CTCTGTTGTCTTAAACAAGAG
A-3′]), DNA products specific for each dengue virus sero-
type were generated.
NS1 antigen detection by ELISA
The Platelia™ Dengue NS1 Ag-ELISA (BioRad Laborator-
ies, France) was used for NS1 antigen capture according
to the instructions by the manufacturer.
Immunologic markers
We performed the Panbio® dengue IgM Capture ELISA
(Alere™, Minas Gerais, Brasil) and Dengue Virus IgG
DxSelect™ ELISA (Focus Diagnostics, California, USA) ac-
cording to the manufacturers’ instructions for the qualita-
tive detection of anti-DENV IgM and anti-DENV IgG
antibodies, respectively.
Case definition
Since we aimed to describe only dengue 4 cases, a den-
gue (D4) case was defined as a patient confirmed with
DENV-4 by RT-PCR. Furthermore, acute DENV-4 cases
were classified as primary or secondary infections ac-
cording to the absence or presence of anti-dengue IgG.
A non dengue (ND) case was defined as a patient with
negative results for all dengue biomarkers (viral genome
from any serotype, anti-dengue IgM and NS1).
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Patients with negative RT-PCR and Platelia™ Dengue
NS1 Ag-ELISA and/or dengue IgM positive results were
considered indeterminate [29]. Indeterminate cases and
patients with dengue infection by serotypes other than
DENV-4 were excluded.
Laboratory personnel performing one test were blinded
to the results of other tests.
Data processing and analysis
All clinical and laboratory data were collected and re-
corded in a database using the EpiData© 3.1 software [30].
Exploratory analysis was performed using the SPSS© v 17.0
software (SPSS Inc., Chicago, Illinois). MedCalc© 14.8.1
program was used to calculate 95 % confidence intervals
(CI) for sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV), and likelihood ra-
tios of NS1 Bioeasy™ and dengue clinical criteria.
A sample size of 137 positive dengue patients was de-
termined as necessary to estimate, with 95 % confidence
level, a sensitivity of 85 % with an absolute error of 6 %.
Considering a prevalence of 40 % among febrile patients,
342 febrile subjects should be evaluated.
Role of funding source
The Brazilian National Council of Scientific and Techno-
logical Development (CNPq) funded this study (PROEP
402068/2012, REBRATS 401366/2013-8 and Grant level 2
CNPq 311414/2013-3); however, the funder was not in-
volved in the design, sample handling, analysis, data inter-
pretation, conclusions or decision to publish.
Results
In this study, we evaluated a total of 375 acutely febrile
patients. Of those, 38 (10.1 %) were excluded, for rea-
sons shown in Fig. 1. For this reason, 12 patients in the
RT-PCR negative group were excluded for presenting
positive or indeterminate results for specific dengue IgM
or Platelia™ Dengue NS1 Ag-ELISA (Fig. 1).
From the 325 patients included in the study, 148
(45.5 %) had confirmed DENV-4 infection. No significant
differences in age and gender distributions were observed
Fig. 1 STARD flow diagram of febrile Rio de Janeiro, March–April, 2013
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between D4 and ND groups. The hematocrits were similar
in both groups, but the platelet and leukocyte counts were
lower among D4 patients (Table 1). The median time from
onset of symptoms and medical care was 2 days in both
groups.
The secondary infections, defined by anti-dengue IgG
detection in the D4 group, were characterized in 124/
148 (83.7 %) patients, and the NS1 strip test sensitivity
was lower (42 %) in secondary (52/124) than in primary
dengue cases (62.5 %; 15/24), p = 0.05.
We also tested the agreement between the NS1 Bioeasy™
test and the Platelia™ Dengue NS1 Ag-ELISA. The overall
agreement, positive and negative concordances between
the tests were 84.1, 83.5 and 84.7 %, respectively.
Clinical and laboratory features of eligible patients
are shown in Table 2. No sign or symptom alone was
able to predict dengue, although leukopenia and
thrombocytopenia were more frequent in D4 cases.
Leukocyte counts below 4500/mm3 were almost eight
times more likely to be present in D4 cases. In our study
population, we did not find warning signs such as nuchal
rigidity, altered consciousness, and ascites.
Using the WHO 1997 diagnostic criteria, a total of 145
(97.8 %) D4 and 172 (97.2 %) ND were clinically classified
as dengue suspected cases, with a sensitivity of 97.8 % and
specificity of 2.8 %. The WHO 2009 criteria clinically clas-
sified as dengue 129 (87.1 %) D4 and 134 (75.7 %) ND
with 87.1 % sensitivity and 24.3 % specificity. The INI-
FIOCRUZ clinical prediction rule classified as dengue sus-
pected 105 (70.9 %) D4 patients but also 50 (28.2 %) ND,
with a sensitivity of 70.9 % and specificity of 71.8 %
(Table 3).
The NS1 Bioeasy™ immunochromatographic strip test
alone was more accurate than the clinical criteria (OR =
34.4) and showed high specificity (97.8 %). However, the
test sensitivity was lower (44.5 %). The test incorrectly
classified as ND more than half of dengue patients
(55.2 %). With these results almost a third of the pa-
tients with a negative NS1 Bioeasy™ test in our setting
were in fact confirmed dengue cases (PPV = 68.3 %).
Combining the NS1 test with any clinical criteria did
not improve the sensitivity or alter the high false nega-
tive rates, which remained similar to those obtained by
the test alone. But all the evaluated clinical criteria could
be complemented by this test resulting in an almost per-
fect specificity in a clinical setting.
Discussion
This is the first study we are aware of that assesses the
combined accuracy of dengue clinical criteria and a NS1
point-of-care immunoassay for early diagnosis in outpa-
tients during a DENV-4 epidemic. The WHO 1997
criteria was better to rule out the disease. When the INI-
FIOCRUZ clinical criteria was positive, then the NS1
rapid test should be done. Patients with a positive strip
test should be treated as dengue cases; however, negative
results should be monitored for dengue or other acute fe-
brile illnesses. As the clinical diagnosis lacks specificity, a
definitive dengue case may need laboratory confirmation.
According to Lima, et al. [17], RT-PCR used in the
present research showed 90 % sensitivity and more than
95 % specificity on the second day after the onset of dis-
ease, the same median time obtained in our sample. It is
reasonable to consider this as a good diagnostic tool to
confirm dengue fever. However, considering false negative
results, we excluded 12 patients with negative RT-PCR
and a positive or indeterminate IgM or Platelia™ NS1 re-
sults in which we could not identify the serotype.
At the time the study population was evaluated, there
were no reports of any other Flavivirus circulating simul-
taneously in the city of Rio de Janeiro that could interfere
in dengue laboratory results. We believe that we obtained
a true non-dengue set of patients.
We also evaluated the ability of hematological parame-
ters and individual signs and symptoms to discriminate
dengue from non-dengue. We found that leukopenia was
more frequent in D4 than in ND, although the overlap-
ping range between the two groups prevented an adequate
discrimination between them. The relevance of leukopenia
as a discriminant feature of dengue infection has been
previously documented, although the cutoff values may
vary [13, 31–34].
The platelet counts were lower in the D4 group, although
true thrombocytopenia was infrequent in both groups.
Similar to findings in other studies [22, 35], there was no
significant difference in hematocrit between groups. This
may be because both hemoconcentration and platelet drop
are usually not seen in the first days of disease [34].
Table 1 Epidemiological characteristics of 325 febrile patients, Rio de Janeiro, March–April, 2013
Median (IQR)
Dengue 4 (N = 148) Non dengue (N = 177) p-value
Age in years 36.6 (23.1–50.1) 36.5 (23.0–50.0) 0.99
Hematocrit (%) 42.6 (40.3–45.0) 42.2 (40.0–44.0) 0.45
Leucocyte counts (cells/mm3) 4251 (3400–4667) 7518 (5467–7900) <0.05
Platelet counts (cells/ mm3) 217.812 (187,667–236,667) 256,4945 (221,000–284,667) <0.05
IQR interquartile range
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Repeated monitoring of the platelet count and hematocrit
is recommended, as an abrupt fall in platelet count is pro-
posed as a warning sign, and a significant hematocrit in-
crease is an indirect sign of plasma leakage [10, 34].
Gan, et al. [36] studied 256 adults in Singapore and re-
ported 87.1 % sensitivity and 26 % specificity for the
WHO 2009 criteria, similar to the present research. How-
ever, the 20 % sensitivity using the WHO 1997 criteria
was far different from those obtained in our study.
Due to its lower sensitivity (70.9 %), the INI-FIOCRUZ
clinical criteria does not seem very promising as an exclu-
sive screening alternative. However, it was much more
specific than both WHO criteria and showed the best clin-
ical performance for classifying suspected dengue cases. It
could be proposed (and tested in a different population) as
a screening tool to further confirm using more expensive
and time consuming specific laboratory tests.
Among the signs and symptoms in the three sets of
clinical criteria, none was significantly more frequent
among D4 patients. However, conjunctival hyperemia, a
sign used in the INI-FIOCRUZ criteria, had a perform-
ance similar to classic signs, such as exanthema.
Although not sufficiently accurate to be used as a dis-
criminant feature alone, this was an important finding
Table 2 Clinical and laboratory features of 325 febrile patients, Rio de Janeiro, March–April, 2013
Dengue 4 (N = 148) Non dengue (N = 177) OR (95 % CI)
N % N %
Clinical
Exanthema 28 18.9 21 11.8 1.7 (0.9–3.2)
Conjunctival hyperemia 75 50.6 72 40.6 1.5 (1–2.3)
Lethargya 142 95.9 168 94.9 1.3 (0.4–3.6)
Joint pain 110 74.3 128 72.3 1.1 (0.7–1.8)
Pain 143 96.6 171 96.6 1.0 (0.3–3.4)
Retro-orbital pain 105 70.9 124 70.0 1.0 (0.6–1.7)
Nausea/vomiting 99 66.9 120 67.7 1.0 (0.6–1.5)
Edemaa 3 2.0 4 2.2 0.9 (0.2–4.0)
Liver enlargementa 4 2.7 6 3.3 0.8 (0.2–2.9)
Persistent vomitinga 35 23.6 48 27.1 0.8 (0.5–1.4)
Myalgia 134 90.5 161 90.9 0.9 (0.4–1.9)
Abdominal tendernessa 47 31.7 68 38.4 0.7 (0.5–1.2)
Bleedinga 12 8.1 25 14.1 0.5 (0.3–1.1)
Headache 133 89.8 169 95.4 0.4 (0.2–1. 0)
Laboratory
Leukopenia 95 64.1 33 18.6 7.8 (4.7–13.0)b
Thrombocytopenia 17 11.4 8 4.5 2.7 (1.1–6.5)b
Anti-dengue IgG 123 83.1 161 90.9 0.5 (0.3–1.0)
OR odds ratio, CI confidence interval
awarning signs; Leukopenia = leucocyte count <4,500cells/mm3; thrombocytopenia = platelet count <150,000 cells/mm3
bsignificant odds ratio















WHO 1997 97.8 (93.8–99.6) 2.8 (1.0–6.9) 1.0 (1.0–1.1) 0.7 (0.2–3.0) 45.6 (39.9–51.5) 62.5 (24.5–91.5) 1.4 (0.3–6.0)
WHO 2009 87.1 (80.3–92.1) 24.3 (18.1–31.6) 1.1 (1.0–1.3) 0.5 (0.3–0.9) 48.8 (42.4–55.2) 69.5 (56.1–80.8) 2.2 (1.2–4.0)
INI-FIOCRUZ 70.9 (63.2–78.6) 71.8 (64.5–78.4) 2.5 (2.0–3.3) 0.4 (0.3–0.5) 67.6 (59.5–74.9) 75.3 (68.0–81.7) 6.4 (3.9–10.4)
NS1 44.5 (36.4–53.3) 97.8 (94.2–99.4) 19.5 (7.3–52.2) 0.6 (0.5–0.7) 94.1 (85.6–98.4) 68.3 (62.1–74.0) 34.4 (12.1–97.9)
WHO 1997 and NS1 44.2 (35.8–52.9) 97.6 (94.0–99.3) 18.3 (6.8–49.2) 0.6 (0.5–0.7) 93.9 (85.0–98.3) 67.8 (61.4–73.7) 32.1 (11.3–91.4)
WHO 2009 and NS1 40.6 (32.3–49.3) 98.2 (94.9–99.6) 22.6 (7.2–70.6) 0.6 (0.5–0.7) 94.9 (85.9–98.9) 66.7 (60.4–72.5) 37.3 (11.3–122.9)
INI-FIOCRUZ and NS1 29.7 (22.4–37.8) 98.9 (96.0–99.9) 26.2 (6.5–106.5) 0.7 (0.6–0.8) 95.6 (84.9–99.5) 63.2 (57.2–68.9) 36.9 (8.7–155.5)
LR+ positive likelihood ratio, LR− negative likelihood ratio, PPV positive predictive value, NPV negative predictive value, OR odds ratio, CI confidence interval
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because this clinical sign is not included in the WHO
criteria. At least three other studies have reported simi-
lar results, both in febrile outpatients in early disease
stages [13, 35, 37].
As described by Leo, et al. [38] and Paranavitane, et al.
[39] our study targeted early dengue disease in outpatient
setting, therefore we could not assess warning signs such
as nuchal rigidity, altered consciousness, and ascites,
abrupt platelet count fall or hemoconcentration, that
occur later during the disease.
The WHO 2009 dengue criteria improved rates of cor-
rect identification of severe dengue cases, aiding thera-
peutics and avoiding unnecessary deaths [30]. However,
it did not prove to be much more accurate (sensitive) for
screening or clinically diagnosing dengue 4 than the
WHO 1997 version. INI-FIOCRUZ criteria showed the
best-balanced performance and could enhance specificity
being used previously to the NS1 rapid test in selecting
a group of patients for this more specific test.
The NS1 Bioeasy™ showed excellent specificity (97.8 %)
in the study population, which agrees with previous re-
ported results in different countries [15, 40]. However, we
found a substantially lower sensitivity (44.5 %) of Bioeasy™
NS1 immunoassay in our DENV-4 patients compared to
the 61.3 and 90 % sensitivity described respectively by
Ferraz, et al. [22], and Silva, et al. [23] in DENV-1 and
DENV-3 scenarios. Lower sensitivity to DENV-4 com-
pared to the other serotypes has also been documented by
Pal, et al. [15], varying from 42 to 58 % depending on the
test used.
Differing performances according to serotype were also
recently described in a meta-analysis evaluating two NS1
ELISA tests for early dengue detection [18]. The study
concluded that Platelia™ NS1 and NS1 Panbio® tests
showed lower pooled sensitivity for DENV-4 (58 and
37 %, respectively) [18]. The interpretation given by some
authors includes the NS1 gene polymorphism associated
with immunological epitopes, a low NS1 concentration in
DENV-4 cases [20, 41], or low overall viremia [21]. Never-
theless, this latter hypothesis was not confirmed by
Allonso, et al. [20] in a recent Brazilian study.
As reported in other studies on NS1 detection using
conventional ELISA or rapid tests, we observed lower
NS1 Bioeasy™ sensitivity in secondary (42 %) compared to
primary (62.5 %) dengue cases [9, 12, 15, 20]. As most of
the cases (83.7 %) were secondary infections, this might
have contributed to the poor performance of the test in
our population. This low performance probably occurred
due to a rapid clearance in secondary cases [15] and/or as
a result of antigen-antibody complexes that disrupt the
test targets impeding the ability of the test to detect free
NS1 antigen [42, 43]. Efforts to dissociate immune com-
plexes by acid or heat treatment can probably enhance the
assays sensitivities [44].
The high PPV (94.1 %) obtained in this 45.5 % dengue
prevalence scenario, similar to that obtained by Pal, et al.
[15], indicates that individuals testing positive on NS1 do
not require another confirmatory test. The performance
on specificity qualifies this test, as a confirmatory one, to
streamline the decision to treat the correctly identified
dengue patients in the clinical setting. It should be used
just after the onset of symptoms in order to avoid compli-
cations and deaths and to organize the flow of care at the
facility. This rapid test might also be useful for virologic
surveillance purposes to select serum samples for RNA
detection by PCR.
However, although highly specific, the NS1 rapid test
yields high false negative rates (55.5 %) among confirmed
DENV-4 patients, and its low sensitivity argues against its
incorporation as a screening diagnostic tool in clinical
practice. Recently, the Rio de Janeiro State Health Depart-
ment decided not to include the test for dengue screening
in outpatient settings. Its use has been restricted to evalu-
ate critically ill hospitalized patients.
Our study has some limitations: a small sample of pri-
mary dengue patients and the absence of the tourniquet
test, a WHO sign criteria, considered a painful and
lengthy procedure with poor patient compliance. We were
also not able to reevaluate the patients in the convalescent
period due to the pragmatic diagnostic study outline and
the dynamics of the Rio de Janeiro city’s health care sys-
tem. Although the gold standard for dengue diagnosis
would be pairing specific dengue IgM in acute and conva-
lescent period, as proposed by WHO [11], recent studies
have also exclusively used PCR as the reference test to
evaluate early phase dengue [45], to evaluate clinical algo-
rithms [46] or ELISA and NS1 tests [15].
Conclusions
The development of more sensitive point-of-care tests
for dengue diagnosis to act as a screening tool remains a
challenge, especially for endemic countries, where the
prevalence of secondary cases is high. In summary, we
proposed a clinical-laboratory algorithm which combines
the INI-FIOCRUZ and the WHO 1997 clinical criteria,
in order to select ambulatory suspected early dengue
cases (within 3 days of onset of disease) eligible for NS1
strip testing. The patients that test positive should be
immediately treated for dengue, and the patients that
test negative would still require subsequent diagnostic
investigation. We recommend external validation in dif-
ferent settings.
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